Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures.

Budzinski JW, Foster BC, Vandenhoek S, Arnason JT.

Phytomedicine. 2000 Jul;7(4):273-82.

PMID:
10969720
2.

St John's Wort: effect on CYP3A4 activity.

Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH.

Clin Pharmacol Ther. 2000 May;67(5):451-7.

PMID:
10824623
3.

The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes.

Hellum BH, Hu Z, Nilsen OG.

Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):23-30.

4.

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.

Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K.

Clin Pharmacol Ther. 2000 Dec;68(6):598-604.

PMID:
11180019
5.
6.

Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?

Gutmann H, Poller B, Büter KB, Pfrunder A, Schaffner W, Drewe J.

Planta Med. 2006 Jun;72(8):685-90. Epub 2006 Jun 1.

PMID:
16755466
7.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2001 Oct;70(4):317-26.

PMID:
11673747
8.

Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products.

Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC.

Can J Physiol Pharmacol. 2007 Sep;85(9):966-78.

PMID:
18066144
9.

MDR- and CYP3A4-mediated drug-herbal interactions.

Pal D, Mitra AK.

Life Sci. 2006 Mar 27;78(18):2131-45. Epub 2006 Jan 25. Review.

PMID:
16442130
10.

In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition.

Hansen TS, Nilsen OG.

Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):445-9. doi: 10.1111/j.1742-7843.2008.00307.x.

11.

In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products.

Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT.

Phytomedicine. 2003 May;10(4):334-42.

PMID:
12809364
13.

Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes.

Ganzera M, Schneider P, Stuppner H.

Life Sci. 2006 Jan 18;78(8):856-61. Epub 2005 Aug 31.

PMID:
16137701
14.

In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

Patel J, Buddha B, Dey S, Pal D, Mitra AK.

Am J Ther. 2004 Jul-Aug;11(4):262-77.

PMID:
15266218
15.

Effects of herbal products and their constituents on human cytochrome P450(2E1) activity.

Raner GM, Cornelious S, Moulick K, Wang Y, Mortenson A, Cech NB.

Food Chem Toxicol. 2007 Dec;45(12):2359-65. Epub 2007 Jun 15.

16.

Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4).

Modarai M, Yang M, Suter A, Kortenkamp A, Heinrich M.

Planta Med. 2010 Mar;76(4):378-85. doi: 10.1055/s-0029-1186152. Epub 2009 Sep 29.

PMID:
19790031
17.

Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content.

Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A.

J Pharm Pharmacol. 2007 Apr;59(4):567-73.

PMID:
17430641
18.

Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes.

Zadoyan G, Fuhr U.

Planta Med. 2012 Sep;78(13):1428-57. doi: 10.1055/s-0031-1298536. Epub 2012 May 15. Review.

19.

An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic.

Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S.

J Pharm Pharm Sci. 2001 May-Aug;4(2):176-84.

20.

Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL.

Drug Metab Dispos. 2000 Dec;28(12):1440-8.

Supplemental Content

Support Center